GENETRON S5 is based on the proprietary One-Step Seq Method. Credit: Business Wire

China-based precision oncology company Genetron Health has secured regulatory approval from the National Medical Products Administration (NMPA) of China for its semiconductor-based next-generation sequencing (NGS) system, GENETRON S5.

GENETRON S5 is a sequencing system that can identify pH value alterations in nucleotides. As it does not need fluorescence or camera scanning, it allows quicker, simpler and more cost-effective tests with smaller sample size.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Through high-speed semiconductor sequencing technology, the desktop medium-throughput semiconductor-based NGS system can produce high-quality sequencing data to aid laboratory technicians to move from DNA library to data within a timeframe of 24 hours.

The NGS System comes from the proprietary One-Step Seq Method, which helps to prepare quality libraries from input samples of just 10ng within 1.5 hours.

Genetron Health co-founder and CEO Sizhen Wang said: “The approval of GENETRON S5 provides another excellent choice for clinical laboratories and adds another powerful instrument for the standardization of molecular diagnosis.

“GENETRON S5 will deliver high-quality laboratory testing while providing data for clinical use and precision medicine in a much faster manner.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the company, the technology can be applied alongside early screening, diagnosis, treatment guidance and continuous monitoring. The firm has developed diagnostic assays, which can identify lung cancer, urothelial cancer, breast cancer, gliomas and thyroid cancer.

Wang said: “Since our establishment, Genetron Health has explored new technology and areas of application while adapting to changes in the industry landscape to improve precision medicine in China.

“Working with clinical experts and our strategic partners, we have made progress in the field of in vitro diagnostic devices (IVD). The efficiency and speed of GENETRON S5 makes it possible for clinical organisations to help many more cancer patients.”